InnoCare bags Chinese rights to Incyte CAR-T rival Monjuvi in bid to expand in-house pipeline

Jason Mast

Editor

Merck veteran Jasmine Cui has turned Beijing-based InnoCare into a $4 billion company largely on the strength of a single BTK inhibitor and a clutch …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

InnoCare bags Chinese rights to Incyte CAR-T rival Monjuvi in bid to expand in-house pipeline

Jason Mast

Editor

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases

In­no­Care bags Chi­nese rights to In­cyte CAR-T ri­val Mon­ju­vi in bid to ex­pand in-house pipeline

Jason Mast

Editor

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

InnoCare bags Chinese rights to Incyte CAR-T rival Monjuvi in bid to expand in-house pipeline

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases